Radiosynthesis of 68Ga-labelled DOTA-biocytin (68Ga-r-BHD) and assessment of its pharmaceutical quality for clinical use

Mattia Asti, Michele Iori, Paola A. Erba, Giulia Atti, Daniela Farioli, Claudio Guidotti, Annibale Versari

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVES: Biocytin analogues labelled with indium-111, yttrium-90 and lutetium-177 have shown their effectiveness in the imaging of infections/inflammation in patients with osteomyelitis and function as efficient tools in pretargeted antibody-guided radioimmunotherapy. In this study, the labelling of a biocytin analogue coupled with DOTA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid), namely, r-BHD, with gallium-68 (Ga) was optimized, and the quality and stability of the preparations were assessed for clinical use. MATERIALS AND METHODS: Synthesis of Ga-r-BHD was carried out by heating a fraction of the Ge/Ga eluate in a reactor containing the biocytin analogue with the appropriate buffer. The influence of the precursor amount (from 2.5 to 140 nmol), the pH of the reaction (from 2 to 5.5) and the buffer species (1.5 mol/l sodium acetate, 1.5 mol/l sodium formate, 4.5 mol/l HEPES) on radiochemical yield and radiochemical purity was assessed. Studies on stability and binding to avidin (Av) were also conducted in different media. RESULTS: Under the best labelling condition (56 nmol of precursor, 3.8 pH, sodium formate buffer) synthesis of Ga-r-BHD resulted in a yield of 64±3% (not decay corrected). Radiochemical purity was around 95% because a Ga-coordinated sulfoxide form of the ligand was detected as a by-product of the reaction (Ga-r-SBHD). The by-product was identified and characterized by liquid chromatography-electrospray ionization tandem mass spectrometry. At the natural 1 : 4 Av/Ga-r-BHD molar ratio, affinity results were 62±2 and 80±2% in saline and human serum, respectively. Stability of Ga-r-BHD and of the radiotracer/Av complex remains almost constant over 180 min. Ga-r-BHD appears to be a good candidate for clinical applications.

Original languageEnglish
Pages (from-to)1179-1187
Number of pages9
JournalNuclear Medicine Communications
Volume33
Issue number11
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Gallium
formic acid
Pharmaceutical Preparations
Avidin
Buffers
sulfoxide
Lutetium
HEPES
Radioimmunotherapy
Yttrium
biocytin
Sodium Acetate
Indium
Electrospray Ionization Mass Spectrometry
Osteomyelitis
Tandem Mass Spectrometry
Liquid Chromatography
Heating
Ligands
Inflammation

Keywords

  • 68Ga-labelling
  • 68Ga-r-BHD
  • DOTA-biocytin analogues
  • gallium radionuclides
  • imaging of infection/inflammation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Radiosynthesis of 68Ga-labelled DOTA-biocytin (68Ga-r-BHD) and assessment of its pharmaceutical quality for clinical use. / Asti, Mattia; Iori, Michele; Erba, Paola A.; Atti, Giulia; Farioli, Daniela; Guidotti, Claudio; Versari, Annibale.

In: Nuclear Medicine Communications, Vol. 33, No. 11, 11.2012, p. 1179-1187.

Research output: Contribution to journalArticle

Asti, Mattia ; Iori, Michele ; Erba, Paola A. ; Atti, Giulia ; Farioli, Daniela ; Guidotti, Claudio ; Versari, Annibale. / Radiosynthesis of 68Ga-labelled DOTA-biocytin (68Ga-r-BHD) and assessment of its pharmaceutical quality for clinical use. In: Nuclear Medicine Communications. 2012 ; Vol. 33, No. 11. pp. 1179-1187.
@article{3f12386c3160491294b1f5d0b62983e8,
title = "Radiosynthesis of 68Ga-labelled DOTA-biocytin (68Ga-r-BHD) and assessment of its pharmaceutical quality for clinical use",
abstract = "OBJECTIVES: Biocytin analogues labelled with indium-111, yttrium-90 and lutetium-177 have shown their effectiveness in the imaging of infections/inflammation in patients with osteomyelitis and function as efficient tools in pretargeted antibody-guided radioimmunotherapy. In this study, the labelling of a biocytin analogue coupled with DOTA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid), namely, r-BHD, with gallium-68 (Ga) was optimized, and the quality and stability of the preparations were assessed for clinical use. MATERIALS AND METHODS: Synthesis of Ga-r-BHD was carried out by heating a fraction of the Ge/Ga eluate in a reactor containing the biocytin analogue with the appropriate buffer. The influence of the precursor amount (from 2.5 to 140 nmol), the pH of the reaction (from 2 to 5.5) and the buffer species (1.5 mol/l sodium acetate, 1.5 mol/l sodium formate, 4.5 mol/l HEPES) on radiochemical yield and radiochemical purity was assessed. Studies on stability and binding to avidin (Av) were also conducted in different media. RESULTS: Under the best labelling condition (56 nmol of precursor, 3.8 pH, sodium formate buffer) synthesis of Ga-r-BHD resulted in a yield of 64±3{\%} (not decay corrected). Radiochemical purity was around 95{\%} because a Ga-coordinated sulfoxide form of the ligand was detected as a by-product of the reaction (Ga-r-SBHD). The by-product was identified and characterized by liquid chromatography-electrospray ionization tandem mass spectrometry. At the natural 1 : 4 Av/Ga-r-BHD molar ratio, affinity results were 62±2 and 80±2{\%} in saline and human serum, respectively. Stability of Ga-r-BHD and of the radiotracer/Av complex remains almost constant over 180 min. Ga-r-BHD appears to be a good candidate for clinical applications.",
keywords = "68Ga-labelling, 68Ga-r-BHD, DOTA-biocytin analogues, gallium radionuclides, imaging of infection/inflammation",
author = "Mattia Asti and Michele Iori and Erba, {Paola A.} and Giulia Atti and Daniela Farioli and Claudio Guidotti and Annibale Versari",
year = "2012",
month = "11",
doi = "10.1097/MNM.0b013e3283573e05",
language = "English",
volume = "33",
pages = "1179--1187",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Radiosynthesis of 68Ga-labelled DOTA-biocytin (68Ga-r-BHD) and assessment of its pharmaceutical quality for clinical use

AU - Asti, Mattia

AU - Iori, Michele

AU - Erba, Paola A.

AU - Atti, Giulia

AU - Farioli, Daniela

AU - Guidotti, Claudio

AU - Versari, Annibale

PY - 2012/11

Y1 - 2012/11

N2 - OBJECTIVES: Biocytin analogues labelled with indium-111, yttrium-90 and lutetium-177 have shown their effectiveness in the imaging of infections/inflammation in patients with osteomyelitis and function as efficient tools in pretargeted antibody-guided radioimmunotherapy. In this study, the labelling of a biocytin analogue coupled with DOTA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid), namely, r-BHD, with gallium-68 (Ga) was optimized, and the quality and stability of the preparations were assessed for clinical use. MATERIALS AND METHODS: Synthesis of Ga-r-BHD was carried out by heating a fraction of the Ge/Ga eluate in a reactor containing the biocytin analogue with the appropriate buffer. The influence of the precursor amount (from 2.5 to 140 nmol), the pH of the reaction (from 2 to 5.5) and the buffer species (1.5 mol/l sodium acetate, 1.5 mol/l sodium formate, 4.5 mol/l HEPES) on radiochemical yield and radiochemical purity was assessed. Studies on stability and binding to avidin (Av) were also conducted in different media. RESULTS: Under the best labelling condition (56 nmol of precursor, 3.8 pH, sodium formate buffer) synthesis of Ga-r-BHD resulted in a yield of 64±3% (not decay corrected). Radiochemical purity was around 95% because a Ga-coordinated sulfoxide form of the ligand was detected as a by-product of the reaction (Ga-r-SBHD). The by-product was identified and characterized by liquid chromatography-electrospray ionization tandem mass spectrometry. At the natural 1 : 4 Av/Ga-r-BHD molar ratio, affinity results were 62±2 and 80±2% in saline and human serum, respectively. Stability of Ga-r-BHD and of the radiotracer/Av complex remains almost constant over 180 min. Ga-r-BHD appears to be a good candidate for clinical applications.

AB - OBJECTIVES: Biocytin analogues labelled with indium-111, yttrium-90 and lutetium-177 have shown their effectiveness in the imaging of infections/inflammation in patients with osteomyelitis and function as efficient tools in pretargeted antibody-guided radioimmunotherapy. In this study, the labelling of a biocytin analogue coupled with DOTA (1,4,7,10- tetraazacyclododecane-1,4,7,10-tetraacetic acid), namely, r-BHD, with gallium-68 (Ga) was optimized, and the quality and stability of the preparations were assessed for clinical use. MATERIALS AND METHODS: Synthesis of Ga-r-BHD was carried out by heating a fraction of the Ge/Ga eluate in a reactor containing the biocytin analogue with the appropriate buffer. The influence of the precursor amount (from 2.5 to 140 nmol), the pH of the reaction (from 2 to 5.5) and the buffer species (1.5 mol/l sodium acetate, 1.5 mol/l sodium formate, 4.5 mol/l HEPES) on radiochemical yield and radiochemical purity was assessed. Studies on stability and binding to avidin (Av) were also conducted in different media. RESULTS: Under the best labelling condition (56 nmol of precursor, 3.8 pH, sodium formate buffer) synthesis of Ga-r-BHD resulted in a yield of 64±3% (not decay corrected). Radiochemical purity was around 95% because a Ga-coordinated sulfoxide form of the ligand was detected as a by-product of the reaction (Ga-r-SBHD). The by-product was identified and characterized by liquid chromatography-electrospray ionization tandem mass spectrometry. At the natural 1 : 4 Av/Ga-r-BHD molar ratio, affinity results were 62±2 and 80±2% in saline and human serum, respectively. Stability of Ga-r-BHD and of the radiotracer/Av complex remains almost constant over 180 min. Ga-r-BHD appears to be a good candidate for clinical applications.

KW - 68Ga-labelling

KW - 68Ga-r-BHD

KW - DOTA-biocytin analogues

KW - gallium radionuclides

KW - imaging of infection/inflammation

UR - http://www.scopus.com/inward/record.url?scp=84866946079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866946079&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e3283573e05

DO - 10.1097/MNM.0b013e3283573e05

M3 - Article

C2 - 22836735

AN - SCOPUS:84866946079

VL - 33

SP - 1179

EP - 1187

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 11

ER -